Bridge Biotherapeutics Net Income vs. Cash And Equivalents
| 288330 Stock | KRW 4,495 555.00 14.09% |
For Bridge Biotherapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Bridge Biotherapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Bridge Biotherapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Bridge Biotherapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Bridge Biotherapeutics over time as well as its relative position and ranking within its peers.
Bridge |
Bridge Biotherapeutics Cash And Equivalents vs. Net Income Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Bridge Biotherapeutics's current stock value. Our valuation model uses many indicators to compare Bridge Biotherapeutics value to that of its competitors to determine the firm's financial worth. Bridge Biotherapeutics is rated below average in net income category among its peers. It is rated fourth in cash and equivalents category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Bridge Biotherapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Bridge Biotherapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Bridge Cash And Equivalents vs. Net Income
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Bridge Biotherapeutics |
| = | (26.28 B) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Bridge Biotherapeutics |
| = | 8.2 B |
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Bridge Cash And Equivalents Comparison
Bridge Biotherapeutics is rated third in cash and equivalents category among its peers.
Bridge Biotherapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Bridge Biotherapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Bridge Biotherapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Bridge Biotherapeutics' change in net profit over the period of time. It can combine multiple indicators of Bridge Biotherapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Bridge Biotherapeutics, Inc., a clinical stage biotech company, engages in the development of therapeutics for the treatment of ulcerative colitis, fibrotic diseases, and cancers worldwide. The company was founded in 2015 and is headquartered in Seongnam, Korea. BRIDGE BIOTHERAPEUTICS is traded on Korean Securities Dealers Automated Quotations in South Korea.
Bridge Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Bridge Biotherapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Bridge Biotherapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Bridge Biotherapeutics' important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Bridge Biotherapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Share Portfolio Now
Share PortfolioTrack or share privately all of your investments from the convenience of any device |
| All Next | Launch Module |
Use Investing Themes to Complement your Bridge Biotherapeutics position
In addition to having Bridge Biotherapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Sports Thematic Idea Now
Sports
Companies in sporting activities arena as well as manufacturers of sporting goods and sport retailers. The Sports theme has 25 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Sports Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Bridge Stock
To fully project Bridge Biotherapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Bridge Biotherapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Bridge Biotherapeutics' income statement, its balance sheet, and the statement of cash flows.